Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315491 · ClinicalTrials.gov registry record · Phase 2
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
A Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma, sponsored by Cybrexa Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT06315491: Recruiting Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma, sponsored by Cybrexa Therapeutics.
NCT06315491 is a Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma that is actively recruiting participants, run by Cybrexa Therapeutics. The registered enrollment target is 40 participants, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (78% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06315491, a Phase 2 study of Platinum-resistant Ovarian Cancer and Refractory Ovarian Carcinoma, is actively recruiting participants, sponsored by Cybrexa Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Primary Outcome
ORR is defined as the proportion of subjects achieving a confirmed best overall response (BOR) of CR or PR defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Conditions Studied
Interventions
- DRUG CBX-12
Study Locations (17)
Arizona
- Honor Health - Scottsdale
- Arizona Oncology Associates - Tucson
Florida
- D&H Cancer Research Center - Margate
- South Florida Gynecology - Tampa
New York
- Pci Nyu Langone Health - New York
- Albert Einstein College of Medicine Montefiore Medical - New York
Texas
- Mary Crowley Cancer Research - Dallas
- Texas Oncology- Gulf Coast - The Woodlands
California
- Usc Norris Comprehensive Cancer Center - Los Angeles
Connecticut
- Yale University School of Medicine - New Haven
Indiana
- Northwest Cancer Centers - Dyer
Kentucky
- Norton Cancer Institute - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-10 |
| Phase | Phase 2 |
What NCT06315491 shows while recruiting
NCT06315491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 184-participant average among 17 other Platinum-resistant Ovarian Cancer trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Platinum-resistant Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBX-12 is the first listed.
NCT06315491 lists 17 locations in 13 states (Arizona, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT06315491 about?
NCT06315491 is a clinical study titled "A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer". The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
What is the current status of trial NCT06315491?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-09-25. Estimated completion is 2025-10.
What conditions does trial NCT06315491 study?
This clinical trial studies the following conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma.
What interventions are being tested in trial NCT06315491?
The interventions under investigation include: CBX-12 (DRUG).
Who is sponsoring clinical trial NCT06315491?
This trial is sponsored by Cybrexa Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315491 being conducted?
This trial has 17 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-resistant Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06315491's enrollment target sits among peer trials
40 14th of 17 higher than 4 of 17 other Platinum-resistant Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Platinum-resistant Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
RECRUITING · Phase 2
-
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
ACTIVE NOT RECRUITING · Phase 2
-
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
RECRUITING · Phase 1
-
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI